Tango Therapeutics, Inc. TNGX

24.92 0.29 1.18% as of 25 Sep
Market cap
$4.2B
P/E
0.0×
Growth Flags show if company had growth for consecutive years
Dec '17 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
— — 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
— — 0.00 18.34 25.82 25.84 8.02 16.50
P/FCF ratio
— — 0.00 0.00 0.00 0.00 0.00 0.00
P/Operating CF
— — (1,027.12) (40.20) (22.71) (34.36) (9.21) (34.63)
P/B ratio
— — 1.51 1.97 2.57 3.73 1.69 2.97
Price to Tangible BV
— — 1.51 1.97 2.57 3.73 1.69 2.97
EV/Sales
— — 0.00 5.23 11.07 16.59 1.89 10.99
EV/EBITDA
— — 0.00 0.00 0.00 0.00 0.00 0.00
EV/Operating CF
— — 0.00 (3.25) (2.52) (5.14) (0.61) (4.94)
EV/FCF
— — 0.00 (3.16) (2.36) (5.07) (0.60) (4.90)
Quick Ratio
— — 4.70 11.99 6.64 7.35 6.76 15.85
Current Ratio
— — 4.73 12.10 6.76 7.54 6.98 16.32
Net Debt/EBITDA
— — 3.70 8.48 3.35 2.93 1.75 3.08
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt/Equity
— — 0.00 0.00 0.00 0.00 0.00 0.00
Asset Turnover
— 0.00 0.07 0.10 0.05 0.09 0.12 0.17
Operating CF/Net income
— — (1.35) 1.02 1.01 1.16 1.01 1.37
Capex/Depreciation
— — (1.54) (2.05) (4.78) 1.56 0.36 2.57
Interest Coverage
— — 0.00 0.00 0.00 0.00 0.00 0.00
ROE
— — (20.50%) (30.38%) (36.41%) (40.49%) (57.58%) (37.23%)
ROA
— 0.00% (50.15%) (16.46%) (23.10%) (24.25%) (36.24%) (28.41%)
ROIC
— — 0.00% 0.00% 0.00% 0.00% 0.00% (2,661.91%)
Return on Tangible Assets
— — (33.20%) (12.76%) (32.72%) (32.77%) (55.15%) (29.97%)
Average Days of Receivables
— — 95.35 19.71 29.36 0.00 0.00 0.00
Research and Development Expense of Revenue
— — 652.96% 209.59% 426.01% 315.38% 342.10% 211.86%
Selling, General and Administrative Expense of Revenue
— — 128.85% 47.50% 120.78% 97.19% 103.99% 66.54%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— — 23.04% 21.15% 57.24% 52.23% 68.69% 42.37%
Graham Net Nets
— — (0.02) 0.50 0.29 0.21 0.44 0.29
Graham Number
— — 0.00 0.00 0.00 0.00 0.00 0.00
Earnings Yield
— — 0.00% (8.58%) (16.83%) (11.02%) (39.16%) (9.71%)
Free Cash Flow Yield
— — 0.00% (9.03%) (18.19%) (12.66%) (39.19%) (13.60%)
Revenue per Share
— — 0.24 0.60 0.28 0.39 0.39 0.54
Operating CF per Share
— — 2.19 (0.96) (1.24) (1.25) (1.20) (1.20)
Capex per Share
— — (0.03) (0.03) (0.09) (0.02) (0.01) (0.01)
Free Cash Flow per Share
— — 2.16 (0.99) (1.33) (1.26) (1.21) (1.20)
Cash per Share
— — 5.96 7.82 4.18 3.57 2.36 2.96
Shareholders Equity per Share
— — 1.21 5.55 2.84 2.68 1.83 2.98
Interest Debt per Share
— — 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— — 1.21 5.55 2.84 2.68 1.83 2.98
Free Cash Flow
— — 68.97 (61.36) (116.77) (119.51) (132.25) (139.93)
Working Capital
— — 152.72 451.65 319.73 300.60 228.17 332.08
Capital Expenditures
— — (1.11) (1.84) (7.69) (1.53) (0.75) (1.05)
Net Current Asset Value
— — 24.98 336.93 188.28 197.08 149.37 301.25
EV/EBIT
— — 0.00 0.00 0.00 0.00 0.00 0.00
Capex to Sales
— — 0.14 0.05 0.31 0.04 0.02 0.02
Net Profit Margin
— — (678.84%) (157.21%) (435.14%) (278.54%) (309.73%) (162.85%)
Price to Operating Income
— — 0.00 0.00 0.00 0.00 0.00 0.00
Other line items
Depreciation/Fixed assets
— — 0.19 0.19 0.15 (0.10) (0.26) (0.06)
Cash ROIC
— — 28.94% (7.75%) (19.47%) (21.65%) (30.52%) (21.13%)
Accounts Receivable Turnover
— — 3.83 18.52 12.43 0.00 0.00 0.00
Accounts Payable Turnover
— — 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— — 0.00 0.00 0.00 — — —
Average Days of Payables
— — 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— — 0.00 0.00 0.00 — — —
Average Receivables
— — 2.00 2.00 2.00 — — —
Average Payables
— — 2.53 2.53 3.84 3.62 2.19 1.39
Average Assets
— 0.00 103.63 353.70 468.31 419.52 359.53 357.59
Average Common Equity
— — 253.55 191.67 297.11 251.29 226.31 272.85

Fold the line items

Columns are period end dates